Actively Recruiting
Evaluating the MEX-CD1 Device for Extracorporeal Iron Removal in Patients with Myelodysplastic Syndrome or Myelofibrosis Unable to Use Standard Chelation
Led by Hospices Civils de Lyon · Updated on 2026-10-13
13
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Patients with transfusion-dependent myelodysplastic syndromes MDS or myelofibrosis often experience iron overload due to frequent blood transfusions. This overload can damage organs, disrupt hormones, and increase infection risk, affecting survival. Standard oral iron chelation treatments can be intolerable for some. The MEX-CD1 device offers a new extracorporeal approach to reduce iron levels and is being studied for feasibility, safety, and effectiveness in these patients. The study evaluates three consecutive low-volume continuous veno-venous hemodialysis sessions using the MEX-CD1 device within one week. This device delivers a hyper-chelating colloidal solution added to dialysate during hemodialysis. Non-hospitalized patients receive treatment on an outpatient basis. After these sessions, follow-up visits occur at 7, 28, and 90 days to monitor long-term effects. Participants will be assessed for iron reduction during and after treatment, safety, blood product needs, and quality of life. Researchers collect data on treatment delivery, blood volume processed, and patient-reported tolerability. Overall participation spans treatment and follow-up, totaling several months to evaluate device impact and patient experience.
CONDITIONS
Brief Title
Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
Research Team
A
Auguste DARGENT, MD, PhD
B
Bernard ALLAOUCHICHE, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here